| 10.01.2025 07:49 | IQAI | IB and Prism Secure First Installation | RNS |
| 20.11.2024 07:00 | IQAI | Imaging Biometrics Expands Distribution | RNS |
| 05.11.2024 07:00 | IQAI | New Patent Application and Trading Update | RNS |
| 15.10.2024 10:28 | BRH, IQAI | Holding(s) in Company | RNS |
| 15.10.2024 07:00 | IQAI | IQ-AI Issues Letter to Shareholders | Reach |
| 14.10.2024 12:08 | IQAI | Holding(s) in Company | RNS |
| 14.10.2024 12:05 | IQAI | PDMR dealing and TR1 announcement | RNS |
| 14.10.2024 10:05 | BRH, IQAI | IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown | Alliance |
| 11.10.2024 10:42 | IQAI | Acquisition of Interest by Braveheart | RNS |
| 16.08.2024 20:40 | GGP, GBP, SBDS | TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet | Alliance |
| 13.08.2024 14:53 | IQAI | Half-year Report | RNS |
| 25.06.2024 11:56 | IQAI | IN BRIEF: IQ-AI subsidiary opens expanded access programme | Alliance |
| 25.06.2024 09:59 | IQAI | IB Opens Expanded Access Program | RNS |
| 14.06.2024 14:32 | IQAI | IQ-AI team begins defining phase 2 protocol for oral gallium maltolate | Alliance |
| 14.06.2024 08:38 | IQAI | Clinical Trial Updates | RNS |
| 29.05.2024 15:08 | IQAI | Result of AGM | RNS |
| 23.05.2024 21:08 | CEL, AET, PHAR | TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact | Alliance |
| 23.05.2024 07:00 | IQAI | Major East Coast Health System Chooses IB Nimble | RNS |
| 20.05.2024 11:16 | IQAI | IQ-AI subsidiary gets second FDA rare paediatric disease designation | Alliance |
| 20.05.2024 07:10 | IQAI | Second FDA Rare Pediatric Disease Designation | RNS |
| 17.05.2024 17:39 | UKOG, SOHO, TM1 | TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up | Alliance |
| 10.05.2024 15:14 | IQAI | IQ-AI subsidiary gets rare paediatric disease designation FDA | Alliance |
| 10.05.2024 08:15 | IQAI | Rare Pediatric Disease Designation Granted to GaM | RNS |
| 02.05.2024 15:45 | AGFX, UKOG, PGH | EARNINGS AND TRADING: Trident Royalties swings to profit | Alliance |
| 02.05.2024 12:47 | IQAI | IB Announces Expanded Access Program for GaM | RNS |
| 29.04.2024 15:26 | IQAI | Publication of Annual Report | RNS |
| 05.03.2024 07:00 | IQAI | Grant of Options | RNS |
| 01.03.2024 08:22 | IQAI | Holding(s) in Company | RNS |
| 01.03.2024 08:20 | IQAI | Holding(s) in Company | RNS |
| 26.02.2024 07:00 | IQAI | Result of Broker Option and Total Voting Rights | RNS |
| 22.02.2024 14:02 | IQAI | IN BRIEF: IQ-AI shares sink on discounted placing fundraise | Alliance |
| 22.02.2024 07:00 | IQAI | Placing and Broker Option | RNS |
| 09.02.2024 13:38 | IQAI | IQ-AI subsidiary asked by FDA to resubmit and modify application | Alliance |
| 02.02.2024 08:56 | IQAI | IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary | Alliance |
| 22.01.2024 10:05 | IQAI | Holding(s) in Company | RNS |
| 15.01.2024 07:01 | IQAI | Director Dealings and Conversion of CLNs | RNS |
| 15.01.2024 07:00 | IQAI | Holding(s) in Company | RNS |
| 10.01.2024 11:48 | IQAI | IQ-AI falls after subsidiary notes launch of treatment access scheme | Alliance |
| 10.01.2024 07:00 | IQAI | IB Launching an Expanded Access Program for GaM | RNS |
| 19.12.2023 17:00 | IQAI | IQ-AI firm gets US FDA fast-track status for oral gallium maltolate | Alliance |
| 19.12.2023 14:29 | IQAI | Imaging Biometrics granted FDA “Fast-Track” | RNS |
| 05.12.2023 11:49 | IQAI | IQ-AI stock rises on positive interim results from glioblastoma trial | Alliance |
| 05.12.2023 10:58 | IQAI | IQ-AI Announces Positive Interim Phase 1 Results | RNS |
| 20.11.2023 13:42 | IQAI | Holding(s) in Company | RNS |
| 09.11.2023 11:38 | IQAI | Director Dealing and Conversion of CLNs | RNS |
| 08.11.2023 12:04 | IQAI | IQ-AI says Imaging Biometrics submits paediatric rare disease request | Alliance |
| 08.11.2023 10:59 | IQAI | Application for Pediatric Rare Disease Designation | RNS |
| 06.11.2023 13:02 | IQAI | Holding(s) in Company | RNS |
| 18.10.2023 17:11 | IQAI | IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study | Alliance |
| 18.10.2023 14:29 | IQAI | Update Regarding Imaging Biometrics LLC | RNS |
| 13.10.2023 08:55 | IQAI | IB Letter to Shareholders | RNS |
| 09.10.2023 12:09 | IQAI | IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA | Alliance |
| 09.10.2023 07:00 | IQAI | Orphan Drug Status to GaM and Total Voting Rights | RNS |
| 03.10.2023 11:30 | IQAI | Holding(s) in Company | RNS |
| 19.09.2023 14:32 | IQAI | IQ-AI shares cease trading on the OTCQB | RNS |
| 08.09.2023 10:25 | IQAI | IQ-AI notes vindication of subsidiary's reduced gadolinium approach | Alliance |
| 08.09.2023 07:00 | IQAI | Reduced Gadolinium Approach Validated' | RNS |
| 18.08.2023 12:17 | IQAI | IQ-AI shares jump on subsidiary's GE Healthcare deal | Alliance |
| 18.08.2023 12:06 | IQAI | Update on Collaboration Agreement with Mayo Clinic | RNS |
| 18.08.2023 11:20 | IQAI | IB & GE HealthCare Enter into Commercial Agreement | RNS |
| 17.08.2023 11:21 | IQAI | IQ-AI interim loss narrows amid higher revenue, lower expenses | Alliance |
| 17.08.2023 07:00 | IQAI | Half-year Report | RNS |
| 19.07.2023 10:45 | IQAI | IN BRIEF: IQ-AI subsidiary's app adopted by US medical college | Alliance |
| 19.07.2023 07:00 | IQAI | Imaging Biometrics Installs IB Nimble™ For MCW | Reach |
| 13.07.2023 11:36 | IQAI | IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate | Alliance |
| 13.07.2023 07:00 | IQAI | Orphan Drug Designation for GaM in Pediatric GBM | RNS |
| 27.06.2023 11:47 | IQAI | IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth | Alliance |
| 27.06.2023 07:00 | IQAI | Studies Show GaM Inhibits Pediatric Tumor Growth | Reach |
| 23.05.2023 16:12 | XSG, UKOG, POS | TRADING UPDATES: Harworth optimistic on 2027; Plexus extends agreement | Alliance |
| 23.05.2023 11:02 | IQAI | Result of AGM | RNS |
| 23.05.2023 07:00 | IQAI | AGM Statement | RNS |
| 16.05.2023 15:53 | XSG, WIX, TFIF | UK shareholder meetings calendar - next 7 days | Alliance |
| 03.05.2023 16:14 | IQAI | Notice of AGM | RNS |
| 26.04.2023 14:43 | TPOU, MGCI, CREO | EARNINGS SUMMARY: Third Point Investors NAV per share drops by quarter | Alliance |
| 26.04.2023 07:00 | IQAI | Final Results | RNS |
